---
document_datetime: 2025-12-29 14:35:18
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ipreziv.html
document_name: ipreziv.html
version: success
processing_time: 0.128512
conversion_datetime: 2025-12-29 23:05:41.384639
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ipreziv

[RSS](/en/individual-human-medicine.xml/66944)

##### Withdrawn

This medicine's authorisation has been withdrawn

azilsartan medoxomil Medicine Human Withdrawn

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ipreziv](#news-on)
- [More information on Ipreziv](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 27 October 2014, the European Commission withdrew the marketing authorisation for Ipreziv (azilsartan medoxomil) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Takeda Pharma A/S, which notified the European Commission of its decision not to market the product in the EU for commercial reasons. Ipreziv was granted marketing authorisation in the EU on 07 December 2011 for the treatment of essential hypertension in adults. It belongs to an established class of medicines in the treatment of hypertension.

The product had not been marketed in the EU from the time of the marketing authorisation on 07 December 2011. Ipreziv was a duplicate application to Edarbi, which is marketed in the EU. The marketing authorisation holder will maintain the marketing authorisation for Edarbi.

The European Public Assessment Report (EPAR) for Ipreziv is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Ipreziv : EPAR - Summary for the public

Reference Number: EMA/807106/2011

English (EN) (520.34 KB - PDF)

**First published:** 15/12/2011

**Last updated:** 19/12/2014

[View](/en/documents/overview/ipreziv-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-317)

български (BG) (620.92 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/bg/documents/overview/ipreziv-epar-summary-public_bg.pdf)

español (ES) (521.15 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/es/documents/overview/ipreziv-epar-summary-public_es.pdf)

čeština (CS) (588.1 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/cs/documents/overview/ipreziv-epar-summary-public_cs.pdf)

dansk (DA) (522.61 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/da/documents/overview/ipreziv-epar-summary-public_da.pdf)

Deutsch (DE) (523.5 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/de/documents/overview/ipreziv-epar-summary-public_de.pdf)

eesti keel (ET) (521.06 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/et/documents/overview/ipreziv-epar-summary-public_et.pdf)

ελληνικά (EL) (626.33 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/el/documents/overview/ipreziv-epar-summary-public_el.pdf)

français (FR) (584.81 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/fr/documents/overview/ipreziv-epar-summary-public_fr.pdf)

italiano (IT) (524.56 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/it/documents/overview/ipreziv-epar-summary-public_it.pdf)

latviešu valoda (LV) (592.4 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/lv/documents/overview/ipreziv-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (1.03 MB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/lt/documents/overview/ipreziv-epar-summary-public_lt.pdf)

magyar (HU) (641.67 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/hu/documents/overview/ipreziv-epar-summary-public_hu.pdf)

Malti (MT) (587.66 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/mt/documents/overview/ipreziv-epar-summary-public_mt.pdf)

Nederlands (NL) (521.58 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/nl/documents/overview/ipreziv-epar-summary-public_nl.pdf)

polski (PL) (589.01 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/pl/documents/overview/ipreziv-epar-summary-public_pl.pdf)

português (PT) (537.62 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/pt/documents/overview/ipreziv-epar-summary-public_pt.pdf)

română (RO) (548.34 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/ro/documents/overview/ipreziv-epar-summary-public_ro.pdf)

slovenčina (SK) (585.36 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/sk/documents/overview/ipreziv-epar-summary-public_sk.pdf)

slovenščina (SL) (582.95 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/sl/documents/overview/ipreziv-epar-summary-public_sl.pdf)

Suomi (FI) (514.89 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/fi/documents/overview/ipreziv-epar-summary-public_fi.pdf)

svenska (SV) (521.93 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/sv/documents/overview/ipreziv-epar-summary-public_sv.pdf)

## Product information

Ipreziv : EPAR - Product Information

English (EN) (1023.63 KB - PDF)

**First published:** 15/12/2011

**Last updated:** 19/12/2014

[View](/en/documents/product-information/ipreziv-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-466)

български (BG) (2.36 MB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/bg/documents/product-information/ipreziv-epar-product-information_bg.pdf)

español (ES) (1.03 MB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/es/documents/product-information/ipreziv-epar-product-information_es.pdf)

čeština (CS) (1.92 MB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/cs/documents/product-information/ipreziv-epar-product-information_cs.pdf)

dansk (DA) (1.13 MB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/da/documents/product-information/ipreziv-epar-product-information_da.pdf)

Deutsch (DE) (1.3 MB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/de/documents/product-information/ipreziv-epar-product-information_de.pdf)

eesti keel (ET) (1.03 MB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/et/documents/product-information/ipreziv-epar-product-information_et.pdf)

ελληνικά (EL) (2.4 MB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/el/documents/product-information/ipreziv-epar-product-information_el.pdf)

français (FR) (1.05 MB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/fr/documents/product-information/ipreziv-epar-product-information_fr.pdf)

hrvatski (HR) (405.04 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/hr/documents/product-information/ipreziv-epar-product-information_hr.pdf)

íslenska (IS) (1.19 MB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/is/documents/product-information/ipreziv-epar-product-information_is.pdf)

italiano (IT) (1.09 MB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/it/documents/product-information/ipreziv-epar-product-information_it.pdf)

latviešu valoda (LV) (1.99 MB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/lv/documents/product-information/ipreziv-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.79 MB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/lt/documents/product-information/ipreziv-epar-product-information_lt.pdf)

magyar (HU) (1.91 MB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/hu/documents/product-information/ipreziv-epar-product-information_hu.pdf)

Malti (MT) (2.03 MB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/mt/documents/product-information/ipreziv-epar-product-information_mt.pdf)

Nederlands (NL) (1.11 MB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/nl/documents/product-information/ipreziv-epar-product-information_nl.pdf)

norsk (NO) (1.13 MB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/no/documents/product-information/ipreziv-epar-product-information_no.pdf)

polski (PL) (1.95 MB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/pl/documents/product-information/ipreziv-epar-product-information_pl.pdf)

português (PT) (1.03 MB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/pt/documents/product-information/ipreziv-epar-product-information_pt.pdf)

română (RO) (1.3 MB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/ro/documents/product-information/ipreziv-epar-product-information_ro.pdf)

slovenčina (SK) (1.89 MB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/sk/documents/product-information/ipreziv-epar-product-information_sk.pdf)

slovenščina (SL) (1.8 MB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/sl/documents/product-information/ipreziv-epar-product-information_sl.pdf)

Suomi (FI) (1.11 MB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/fi/documents/product-information/ipreziv-epar-product-information_fi.pdf)

svenska (SV) (1.03 MB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/sv/documents/product-information/ipreziv-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** A31/0006 27/10/2014

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ipreziv : EPAR - All Authorised presentations

English (EN) (469.98 KB - PDF)

**First published:** 15/12/2011

**Last updated:** 19/12/2014

[View](/en/documents/all-authorised-presentations/ipreziv-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-921)

български (BG) (511.36 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/bg/documents/all-authorised-presentations/ipreziv-epar-all-authorised-presentations_bg.pdf)

español (ES) (477.2 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/es/documents/all-authorised-presentations/ipreziv-epar-all-authorised-presentations_es.pdf)

čeština (CS) (493.96 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/cs/documents/all-authorised-presentations/ipreziv-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (469.53 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/da/documents/all-authorised-presentations/ipreziv-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (476.77 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/de/documents/all-authorised-presentations/ipreziv-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (476.07 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/et/documents/all-authorised-presentations/ipreziv-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (513.77 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/el/documents/all-authorised-presentations/ipreziv-epar-all-authorised-presentations_el.pdf)

français (FR) (477.06 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/fr/documents/all-authorised-presentations/ipreziv-epar-all-authorised-presentations_fr.pdf)

íslenska (IS) (474.64 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/is/documents/all-authorised-presentations/ipreziv-epar-all-authorised-presentations_is.pdf)

italiano (IT) (471.38 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/it/documents/all-authorised-presentations/ipreziv-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (500.54 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/lv/documents/all-authorised-presentations/ipreziv-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (958.84 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/lt/documents/all-authorised-presentations/ipreziv-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (494.58 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/hu/documents/all-authorised-presentations/ipreziv-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (491.65 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/mt/documents/all-authorised-presentations/ipreziv-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (475.71 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/nl/documents/all-authorised-presentations/ipreziv-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (468 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/no/documents/all-authorised-presentations/ipreziv-epar-all-authorised-presentations_no.pdf)

polski (PL) (493.06 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/pl/documents/all-authorised-presentations/ipreziv-epar-all-authorised-presentations_pl.pdf)

português (PT) (473.56 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/pt/documents/all-authorised-presentations/ipreziv-epar-all-authorised-presentations_pt.pdf)

română (RO) (485.97 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/ro/documents/all-authorised-presentations/ipreziv-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (494.97 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/sk/documents/all-authorised-presentations/ipreziv-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (483.58 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/sl/documents/all-authorised-presentations/ipreziv-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (471.63 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/fi/documents/all-authorised-presentations/ipreziv-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (472.58 KB - PDF)

**First published:**

15/12/2011

**Last updated:**

19/12/2014

[View](/sv/documents/all-authorised-presentations/ipreziv-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ipreziv Active substance azilsartan medoxomil International non-proprietary name (INN) or common name azilsartan medoxomil Therapeutic area (MeSH) Hypertension Anatomical therapeutic chemical (ATC) code C09CA09

### Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

### Therapeutic indication

Ipreziv is indicated for the treatment of essential hypertension in adults.

## Authorisation details

EMA product number EMEA/H/C/002517 Marketing authorisation holder

Takeda Pharma A/S

Dybendal Alle 10

Marketing authorisation issued 07/12/2011 Withdrawal of marketing authorisation 27/10/2014 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ipreziv : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (579.42 KB - PDF)

**First published:** 11/06/2012

**Last updated:** 19/12/2014

[View](/en/documents/procedural-steps-after/ipreziv-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Ipreziv-H-C-2517-A31-06 : EPAR - Assessment Report - Article 31

Adopted

Reference Number: EMA/PRAC/294920/2014

English (EN) (301.42 KB - PDF)

**First published:** 30/09/2014

**Last updated:** 30/09/2014

[View](/en/documents/variation-report/ipreziv-h-c-2517-a31-06-epar-assessment-report-article-31_en.pdf)

Ipreziv-H-C-2517-A31-06 : EPAR - Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommendat...

English (EN) (48.81 KB - PDF)

**First published:** 30/09/2014

**Last updated:** 30/09/2014

[View](/en/documents/scientific-conclusion/ipreziv-h-c-2517-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendat_en.pdf)

[Other languages (22)](#file-language-dropdown-737)

български (BG) (87.49 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/bg/documents/scientific-conclusion/ipreziv-h-c-2517-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendat_bg.pdf)

español (ES) (50.51 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/es/documents/scientific-conclusion/ipreziv-h-c-2517-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendat_es.pdf)

čeština (CS) (82.81 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/cs/documents/scientific-conclusion/ipreziv-h-c-2517-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendat_cs.pdf)

dansk (DA) (49.01 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/da/documents/scientific-conclusion/ipreziv-h-c-2517-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendat_da.pdf)

Deutsch (DE) (53.54 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/de/documents/scientific-conclusion/ipreziv-h-c-2517-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendat_de.pdf)

eesti keel (ET) (50.6 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/et/documents/scientific-conclusion/ipreziv-h-c-2517-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendat_et.pdf)

ελληνικά (EL) (89.54 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/el/documents/scientific-conclusion/ipreziv-h-c-2517-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendat_el.pdf)

français (FR) (51.91 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/fr/documents/scientific-conclusion/ipreziv-h-c-2517-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendat_fr.pdf)

hrvatski (HR) (80.12 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/hr/documents/scientific-conclusion/ipreziv-h-c-2517-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendat_hr.pdf)

italiano (IT) (51.13 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/it/documents/scientific-conclusion/ipreziv-h-c-2517-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendat_it.pdf)

latviešu valoda (LV) (81.63 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/lv/documents/scientific-conclusion/ipreziv-h-c-2517-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendat_lv.pdf)

lietuvių kalba (LT) (82.54 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/lt/documents/scientific-conclusion/ipreziv-h-c-2517-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendat_lt.pdf)

magyar (HU) (68.7 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/hu/documents/scientific-conclusion/ipreziv-h-c-2517-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendat_hu.pdf)

Malti (MT) (84.23 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/mt/documents/scientific-conclusion/ipreziv-h-c-2517-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendat_mt.pdf)

Nederlands (NL) (49.82 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/nl/documents/scientific-conclusion/ipreziv-h-c-2517-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendat_nl.pdf)

polski (PL) (83.62 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/pl/documents/scientific-conclusion/ipreziv-h-c-2517-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendat_pl.pdf)

português (PT) (49.74 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/pt/documents/scientific-conclusion/ipreziv-h-c-2517-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendat_pt.pdf)

română (RO) (88.19 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/ro/documents/scientific-conclusion/ipreziv-h-c-2517-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendat_ro.pdf)

slovenčina (SK) (81.5 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/sk/documents/scientific-conclusion/ipreziv-h-c-2517-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendat_sk.pdf)

slovenščina (SL) (79.79 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/sl/documents/scientific-conclusion/ipreziv-h-c-2517-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendat_sl.pdf)

Suomi (FI) (49.15 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/fi/documents/scientific-conclusion/ipreziv-h-c-2517-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendat_fi.pdf)

svenska (SV) (50.18 KB - PDF)

**First published:**

30/09/2014

**Last updated:**

30/09/2014

[View](/sv/documents/scientific-conclusion/ipreziv-h-c-2517-a31-06-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommendat_sv.pdf)

Ipreziv-H-C-2517-PSUV-08 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/538715/2013

English (EN) (550.74 KB - PDF)

**First published:** 02/07/2014

**Last updated:** 19/12/2014

[View](/en/documents/scientific-conclusion/ipreziv-h-c-2517-psuv-08-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

CHMP post-authorisation summary of positive opinion for Ipreziv

Adopted

Reference Number: EMA/CHMP/569645/2013

English (EN) (531.8 KB - PDF)

**First published:** 20/09/2013

**Last updated:** 19/12/2014

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-ipreziv_en.pdf)

## Initial marketing authorisation documents

Ipreziv : EPAR - Public assessment report

Adopted

English (EN) (1.72 MB - PDF)

**First published:** 15/12/2011

**Last updated:** 19/12/2014

[View](/en/documents/assessment-report/ipreziv-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Ipreziv

Adopted

Reference Number: EMA/CHMP/737200/2011

English (EN) (510.21 KB - PDF)

**First published:** 23/09/2011

**Last updated:** 19/12/2014

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-ipreziv_en.pdf)

#### News on Ipreziv

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2013) 20/09/2013

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2013](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-may-2013) 17/05/2013

#### More information on Ipreziv

- [Renin-angiotensin-system (RAS)-acting agents - referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)

**This page was last updated on** 19/12/2014

## Share this page

[Back to top](#main-content)